NCT02481050View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 16, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

September 5, 2017

Conditions

Breast Cancer

Interventions

DRUG

Eribulin Mesylate

Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes biweekly on Day 1 and Day 15 of each 28-day cycle.

Trial Locations (12)

12206

Facility #1, Albany

20176

Facility #1, Leesburg

21044

Facility #1, Columbia

22601

Facility #1, Winchester

68130

Facility #1, Omaha

75231

Facility #1, Dallas

75246

Facility #2, Dallas

75702

Facility #1, Tyler

77024

Facility #1, Houston

78217

Facility #1, San Antonio

80218

Facility #1, Denver

97213

Facility #1, Portland

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY

NCT02481050 - Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter